FGFR2 and cholangiocarcinoma: The success of the FGFR inhibitors pemigatinib, erdafitinib, futibatinib, and RLY-4008 in patients with previously treated CCA tumors with FGFR2 fusions or rearrangements29,36, 37, 38, 39, 40 represents a paradigm shift toward personalized medicine.41